Clinical Grade Non-Transfusable Mobilized Peripheral Blood CD133+ Cells, G-CSF + Plerixafor, Frozen
Human CD133 is a transmembrane glycoprotein that is expressed on CD34+ and CD34– multipotent stem and progenitor cells that are involved in hematopoiesis. Unlike CD34+ cells, cord blood CD133+ cells are also expressed on circulating endothelial precursors that are involved in vasculogenesis. Additionally, cord blood CD133+ hematopoietic cells have been found to differentiate in vitro to cells of the ectodermal and mesodermal lineages implying that these cells have the ability to give rise to cells of non-hematopoietic lineages.
Human mobilized peripheral blood CD133+ cells are enriched from the total cell population using direct immunomagnetic anti-CD133 beads. All cell isolation components, including reagents, tubing sets, instruments, and buffers, are manufactured and controlled under an ISO 13485 certified quality system under FDA oversight. Cell culture procedures, including open manipulation of vials, final filling, and closure of finished products, are performed inside ISO 5 air quality processing chambers located within an FDA-registered cell manufacturing facility. Isolated primary cells are characterized by flow cytometry to ensure a highly pure and viable cell population.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols. All reagents and devices used to collect and separate the cells are certified clinical grade. This item is for research use only.
|Cell and Tissue Source||Peripheral Blood|
|Product Type||Primary Cells|
|Cell Type||Stem/Progenitor Cells|
|Donor Attributes||HIV-, HepB-, HepC-|
|Purity||≥90% by Flow Cytometry|
|Viability||≥70% by Flow Cytometry|
|Contains||StemSpan™ and 10% DMSO|
|Injections||10μg/kg/day of G-CSF & 240μg/kg Plerixafor the day before collection|